Skip to main content

Table 6 Current registration and recommended use of Maraviroc in African countries

From: HIV-1 subtype C predicted co-receptor tropism in Africa: an individual sequence level meta-analysis

African countries

Year of registration (Registering authority)

Recommendation in treatment guidelines/remarks

URL links

South Africa

2013 (Medicines Control Council)

Not included in the national treatment guidelines, but the Southern African HIV Clinicians Society recommends its use as salvage therapy

https://www.sahpra.org.za/documents/149a634812.71_Notification_of_Registration_Mar13_v1.pdf

Accessed 20 Jan 2020

https://sahivsoc.org/Files/2014%20Adult%20ART%20Guideline%20(Dec%202014).pdf

Accessed 14 Jan 2020

Tanzania

Information on registration or of the registering authority is not available

Recommended in the national treatment guidelines as a component in third line treatment by the Ministry of Health, Community Development, Gender, Elderly, and Children

https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=2ahUKEwj3rtrNsIXnAhV2QkEAHSBnDuoQFjAAegQIARAC&url=http%3A%2F%2Fwww.nacp.go.tz%2Fsite%2Fdownload%2FNATIONAL_DECEMBER_2017.pdf&usg=AOvVaw0XAyt4IPPIA8OE_-qSR9no

Accessed 14 Jan 2020

Uganda

2008 (National drug register of Uganda Human Medicines)

Currently not recommended in the national treatment guidelines

https://www.nda.or.ug/Linked%20publications/NATIONAL%20DRUG%20REGISTER%20HUMAN%20JANUARY%202020.pdf

Accessed 14 Jan 2020

Zambia

Information on registration or the registering authority is not available

Recommended in the national treatment guidelines as a component in third line treatment by the Ministry of Health

http://www.hivst.org/files1/Final-Zambia-Consolidated-Guidelines_2018-Print.pdf

Accessed 14 Jan 2020

  1. In these four countries, a specialist committee recommends the use of maraviroc based on HIV drug resistance genotyping data for virologic failure, and HIV tropism test